Point-of-care lateral flow assays for tuberculosis and cryptococcal antigenuria predict death in HIV infected adults in Uganda

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Manabe, Yukari C ^a,b   Nonyane, Bareng A S ^c   Nakiyingi, Lydia ^a   Mbabazi, Olive ^a   Lubega, Gloria ^a   Shah, Maunank ^b   Moulton, Lawrence H ^c   Joloba, Moses ^a   Ellner, Jerrold ^d   Dorman, Susan E ^b  

^a MAKERERE UNIVERSITY   (Uganda)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; FLUCONAZOLE; FUNGUS ANTIGEN;

ADULT; ANTIGEN DETECTION; ARTICLE; ASSAY; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CRYPTOCOCCOSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KARNOFSKY PERFORMANCE STATUS; LATERAL FLOW ASSAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; POINT OF CARE TESTING; PREDICTION; SENSITIVITY AND SPECIFICITY; SPUTUM ANALYSIS; TUBERCULOSIS; UGANDA; URINALYSIS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; COMPLICATION; EPIDEMIOLOGY; HOSPITAL INFORMATION SYSTEM; IMMUNOAFFINITY CHROMATOGRAPHY; KAPLAN MEIER METHOD; RISK FACTOR; STATISTICAL MODEL; URINE;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIGENS, FUNGAL; CRYPTOCOCCOSIS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOCHROMATOGRAPHY; KAPLAN-MEIER ESTIMATE; MALE; MODELS, STATISTICAL; POINT-OF-CARE SYSTEMS; RISK FACTORS; TUBERCULOSIS; UGANDA;

EID: 84904382629     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101459     Document Type: Article

References (40)

1. Corbett EL, Marston B, Churchyard GJ, De Cock KM (2006) Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 367: 926-937.
2. Talbot E, Munseri P, Teixeira P, Matee M, Bakari M, et al. (2012) Test characteristics of urinary lipoarabinomannan and predictors of mortality among hospitalized HIV-infected tuberculosis suspects in Tanzania. PLoS ONE 7: e32876.
3. Archibald LK, den Dulk MO, Pallangyo KJ, Reller LB (1998) Fatal Mycobacterium tuberculosis bloodstream infections in febrile hospitalized adults in Dar es Salaam, Tanzania. Clin Infect Dis 26: 290-296. (Pubitemid 28083936)
4. Saleri N, Capone S, Pietra V, De Iaco G, Del Punta V, et al. (2009) Outcome and predictive factors of mortality in hospitalized HIV-patients in Burkina Faso. Infection 37: 142-147.
5. Agaba PA, Digin E, Makai R, Apena L, Agbaji OO, et al. (2011) Clinical characteristics and predictors of mortality in hospitalized HIV-infected Nigerians. J Infect Dev Ctries 5: 377-382.
6. Munseri PJ, Talbot EA, Bakari M, Matee M, Teixeira JP, et al. (2011) The bacteraemia of disseminated tuberculosis among HIV-infected patients with prolonged fever in Tanzania. Scand J Infect Dis 43: 696-701.
7. Cox JA, Lukande RL, Nelson AM, Mayanja-Kizza H, Colebunders R, et al. (2012) An autopsy study describing causes of death and comparing clinicopathological findings among hospitalized patients in Kampala, Uganda. PLoS ONE 7: e33685.
8. Martinson NA, Karstaedt A, Venter WD, Omar T, King P, et al. (2007) Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. Aids 21: 2043-2050. (Pubitemid 47462153)
9. Jacob ST, Moore CC, Banura P, Pinkerton R, Meya D, et al. (2009) Severe sepsis in two Ugandan hospitals: a prospective observational study of management and outcomes in a predominantly HIV-1 infected population. PLoS ONE 4: e7782.
10. Crump JA, Ramadhani HO, Morrissey AB, Saganda W, Mwako MS, et al. (2011) Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected adults and adolescents in northern Tanzania. Clin Infect Dis 52: 341-348.
11. Jacob ST, Banura P, Baeten JM, Moore CC, Meya D, et al. (2012) The impact of early monitored management on survival in hospitalized adult Ugandan patients with severe sepsis: a prospective intervention study*. Crit Care Med 40: 2050-2058.
12. Ssali FN, Kamya MR, Wabwire-Mangen F, Kasasa S, Joloba M, et al. (1998) A prospective study of community-acquired bloodstream infections among febrile adults admitted to Mulago Hospital in Kampala, Uganda. J Acquir Immune Defic Syndr Hum Retrovirol 19: 484-489.
13. Lewis DK, Peters RP, Schijffelen MJ, Joaki GR, Walsh AL, et al. (2002) Clinical indicators of mycobacteraemia in adults admitted to hospital in Blantyre, Malawi. Int J Tuberc Lung Dis 6: 1067-1074. (Pubitemid 36054960)
14. McDonald LC, Archibald LK, Rheanpumikankit S, Tansuphaswadikul S, Eampokalap B, et al. (1999) Unrecognised Mycobacterium tuberculosis bacteraemia among hospital inpatients in less developed countries. Lancet 354: 1159-1163. (Pubitemid 29460445)
15. Shah M, Variava E, Holmes CB, Coppin A, Golub JE, et al. (2009) Diagnostic Accuracy of a Urine Lipoarabinomannan Test for Tuberculosis in Hospitalized Patients in a High HIV Prevalence Setting. J Acquir Immune Defic Syndr.
16. French N, Gray K, Watera C, Nakiyingi J, Lugada E, et al. (2002) Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. Aids 16: 1031-1038. (Pubitemid 34499426)
17. Jarvis JN, Boulle A, Loyse A, Bicanic T, Rebe K, et al. (2009) High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. Aids 23: 1182-1183.
18. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, et al. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525-530.
19. Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, et al. (2007) Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 12: 929-935. (Pubitemid 47245826)
20. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, et al. (2009) Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 48: 856-862.
21. Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, et al. (2010) Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4 + cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis 51: 448-455.
22. Peeling RW, Holmes KK, Mabey D, Ronald A (2006) Rapid tests for sexually transmitted infections (STIs): the way forward. Sex Transm Infect 82 Suppl 5: v1-6. (Pubitemid 46293817)
23. Lawn SD, Dheda K, Kerkhoff AD, Peter JG, Dorman S, et al. (2013) Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies. BMC Infect Dis 13: 407.
24. Lawn SD, Kerkhoff AD, Vogt M, Wood R (2012) Clinical significance of lipoarabinomannan detection in urine using a low-cost point-of-care diagnostic assay for HIV-associated tuberculosis. AIDS 26: 1635-1643.
25. Peter JG, Theron G, van Zyl-Smit R, Haripersad A, Mottay L, et al. (2012) Diagnostic accuracy of a urine LAM strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J.
26. Dorman S, Manabe Y, Nicol M, Nakiyingi L, Moodley M, et al. (2012) Accuracy of the Alere Determine TB-LAM Lateral Flow Test for Diagnosis of Tuberculosis in Adults with HIV Infection: Interim Results from a Multicenter Study. CROI 2012. Seattle.
27. Van Rie A, Jong E, Mkhwanazi M, Sanne I (2013) Diagnosting TB in those Hardest ot Diagnose: Urine Lipoarabionomannan for Suspects of Disseminated and Extrapulmonary TB. Conference on Retroviruses and Opportunistic Infections. Atlanta, GA.
28. Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G, et al. (2011) Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis 53: 1019-1023.
29. Nakiyingi L, Moodley VM, Manabe YC, Nicol MP, Holshouser M, et al. (2014) Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults. J Acquir Immune Defic Syndr.(epub)
30. Andama AO, den Boon S, Meya D, Cattamanchi A, Worodria W, et al. (2013) Prevalence and Outcomes of Cryptococcal Antigenemia in HIV-Seropositive Patients Hospitalized for Suspected Tuberculosis in Uganda. J Acquir Immune Defic Syndr 63: 189-194.
31. Lawn SD, Kerkhoff AD, Vogt M, Wood R (2012) Diagnostic accuracy of a lowcost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis 12: 201-209.
32. Theron G, Pooran A, Peter J, van Zyl-Smit R, Kumar Mishra H, et al. (2012) Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting? Eur Respir J 40: 161-168.
33. Lawn SD, Kerkhoff AD, Vogt M, Ghebrekristos Y, Whitelaw A, et al. (2012) Characteristics and early outcomes of patients with Xpert MTB/RIF-negative pulmonary tuberculosis diagnosed during screening before antiretroviral therapy. Clin Infect Dis 54: 1071-1079.
34. Shah M, Ssengooba W, Armstrong D, Nakiyingi L, Holshouser M, et al. (2014) Comparative performance of urinary lipoarabinomannan assays and Xpert MTB/RIF in HIV-infected individuals with suspected tuberculosis in Uganda. AIDS.
35. Wood R, Racow K, Bekker LG, Middelkoop K, Vogt M, et al. (2012) Lipoarabinomannan in urine during tuberculosis treatment: association with host and pathogen factors and mycobacteriuria. BMC Infect Dis 12: 47.
36. Yoon C, Cattamanchi A, Davis JL, Worodria W, den Boon S, et al. (2012) Impact of Xpert MTB/RIF testing on tuberculosis management and outcomes in hospitalized patients in Uganda. PLoS ONE 7: e48599.
37. Rajasingham R, Meya DB, Boulware DR (2012) Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr 59: e85-91.
38. Micol R, Tajahmady A, Lortholary O, Balkan S, Quillet C, et al. (2010) Costeffectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia. PLoS One 5: e13856.
39. Lawn SD, Ayles H, Egwaga S, Williams B, Mukadi YD, et al. (2011) Potential utility of empirical tuberculosis treatment for HIV-infected patients with advanced immunodeficiency in high TB-HIV burden settings. Int J Tuberc Lung Dis 15: 287-295.
40. de Albuquerque MD, Coimbra I, Batista JD, Maruza M, Ximenes RA, et al. (2014) Empirical treatment for TB in HIV: lessons from a cohort study of people living with HIV treated in Recife, Brazil. BMC Public Health 14: 289.